Effect of subcutaneously administered 2,6,10,14-tetramethylpentadecane on plasmacytoma growth.
2,6,10,14-Tetramethylpentadecane (pristane), s.c. injected simultaneously with plasmacytoma inocula, enhances the transplantability of tumor cells. The effect is dose and time dependent. The enhancement is shown only by plasmacytoma (MOPC-315 and MPC-11) and not by the murine lymphosarcoma and chondrosarcoma tested. Various mechanisms, such as stress and depression of humoral and cellular immunity, have been considered.
D000324:Adrenocorticotropic Hormone / Q000494:pharmacology; D000818:Animals; D000917:Antibody Formation / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D002813:Chondrosarcoma / Q000276:immunology / Q000473:pathology; D004334:Drug Administration Schedule; D005260:Female; D006082:Graft Enhancement, Immunologic; D007279:Injections, Subcutaneous; D008228:Lymphoma, Non-Hodgkin / Q000276:immunology / Q000473:pathology; D051379:Mice; D008807:Mice, Inbred BALB C; D008934:Mitogens / Q000494:pharmacology; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000276:immunology / Q000473:pathology; D010954:Plasmacytoma / Q000276:immunology* / Q000473:pathology; D013154:Spleen / Q000187:drug effects / Q000276:immunology; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D013729:Terpenes / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000494:pharmacology*
D008934:Mitogens; D013729:Terpenes; C009042:pristane; D000324:Adrenocorticotropic Hormone